INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10612179		
Filing Date		2003-03-06		
First Named Inventor	Rolar	nd Kreutzer		
Art Unit		1635		
Examiner Name	Tracy	Ann Vivlemore		
Attorney Docket Number		A2038-706120		

U.S.PATENTS						Remove	
Examine Initial*		Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/T.V./		1	4987071		1991-01-22	CECH ET AL.	
		2	5107065		1992-04-21	SHEWMAKER ET AL.	
		3	5190931		1993-03-02	INOUYE	
		4	5208149		1993-05-04	INOUYE	
		5	5254678		1993-10-19	HASELOFF ET AL.	
		6	5674683		1997-10-07	KOOL	
		7	5719271		1998-02-17	COOK ET AL.	
,		8	5731181		1998-03-24	KMIEC	

(Not for submission under 37 CFR 1.99)

 Application Number
 10612179

 Filing Date
 2003-03-06

 First Named Inventor
 Roland Kreutzer

 Art Unit
 1635

 Examiner Name
 Tracy Ann Vivlemore

 Attorney Docket Number
 A2038-706120

/T.V./	9	5939262		1999-08	3-17	PASLOSKE E	ET AL.				
	10	6025167		2000-02	2-15	CECH ET AL					
\downarrow	11	6573046		2003-06	6-03	KMIEC ET AL					
If you wish	1 to a	⊥ dd additional U.S. Pate	nt citatio	n inform	ation pl	L ease click the	Add button.		Add		_
			U.S.P.	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Part of cited Doc	tentee or Applican ument	Releva		Lines where	
/T.V./	1	20060258608	A1	2006-11	1-16	MEYERS					
If you wisl	1 to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information	please click the A	d button	Add		
				FOREIG	GN PAT	ENT DOCUM	MENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cite Document	d '	where Rel	or Relevant	T5
/T.V./	1	196 31 919 C2	DE								
	2	100 80 167 B4	DE								
\	3	00/44895	wo				KREUTZER ET A	L.			X
		⊥ dd additional Foreign F	1 1-44 D-		-14-41		lana aliah Mas Ad		Add		_

Application Number		10612179
Filing Date		2003-03-06
First Named Inventor	Rolan	d Kreutzer
Art Unit		1635
Examiner Name Tracy		Ann Vivlemore
Attacas Danies News		42020 70C420

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
/T.V./	1	Notice of Opposition by Sima Therapeutics against European Patent No. 11 44 623 (May 28, 2003).	
	2	Nonce of Opposition by Dr. Martin Grund against European Patent No. 11 44 623 (May 28, 2003).	
	3	Notice of Opposition by Atugen AG against European Patent No. 11 44 623 (May 28, 2003).	
	4	Notice of Opposition by Aventis against European Patent No. 11 44 623 (May 28, 2003).	
	5	Notice of Opposition by AstraZeneca against European Patent No. 11 44 623 (May 28, 2003).	
	6	Notice of Opposition by Isis Pharmaceuticals against European Patent No. 11 44 623 (May 28, 2003).	
	7	Notice of Opposition by Novartis against European Patent No. 11 44 623 (May 28, 2003).	
	8	Notice of Opposition by Jenssen Pharmaceuticals against European Patent No. 11 44 623 (May 28, 2003).	
	9	Submission by Alnylam Europe in opposition proceedings for European Patent No. 11 44 623 (December 7, 2004).	
\	10	Submission by Sirna Therapeutics in opposition proceedings for European Patent No. 11 44 623 (April 20, 2006 – Uexkull & Stolberg).	

Application Number		10612179		
Filing Date		2003-03-06		
First Named Inventor	Rolan	d Kreutzer		
Art Unit		1635		
Examiner Name Tracy		Ann Vivlemore		
Attornov Dooket Numb	or	A2038 706120		

/T.V./	11	Submission by Sirna Therapeutics in opposition proceedings for European Patent No. 11 44 623 (April 20, 2006 – Isenbruck, Bosl, Horshchler, Wichmann, Huhn).	
-	12	Submission by atugen in opposition proceedings for European Patent No. 11 44 623 (April 21, 2006).	
	13	Submission by Alnylam Europe in opposition proceedings for European Patent No. 11 44 623 (April 21, 2006).	
	14	Submission by Alnylam Europe in opposition proceedings for European Patent No. 11 44 623 (June 7, 2006).	
	15	Minutes of the Oral Proceedings in opposition proceedings for European Patent No. 11 44 623 (June 22, 2006).	
	16	Interlocutory Decision and Druckexemplar in opposition proceedings for European Patent No. 11 44 623 (September 25, 2006).	
	17	Submission by Alnylam Europe in opposition proceedings for European Patent No. 11 44 623 (June 25, 2007).	
	18	Submission by Sirna Therapeutics in opposition to European Patent No. 1 144 623 (June 12, 2008).	
	19	Communication of Technical Board of Appeal in opposition to European Patent No. 1 144 623 (September 22, 2008). (translation attached)	X
	20	Submission by Atugen AG in opposition to European Patent No.1 144 623 (November 7, 2008).	
1	21	Submission by Sirna Therapeutics in opposition to European Patent No. 1 144 623 (November 6, 2008).	

Application Number		10612179
Filing Date		2003-03-06
First Named Inventor Roland		d Kreutzer
Art Unit		1635
Examiner Name Tracy		Ann Vivlemore
Attorney Docket Numb	er	A2038-706120

/T.V./	22	Submission by Alnylam Pharmaceuticals in the opposition proceedings of European Patent No. 1 144 623 (November 7, 2008). (translation attached)	X
	23	Notice of opposition Quark Biotech against European Patent No. 1 214 945 (March 7, 2006).	
	24	Notice of opposition by Sirna Therapeutics against European Patent No. 1 214 945 (March 7, 2006).	
	25	Notice of opposition by Abbott Laboratories against European Patent No. 1 214 945 (March 8, 2006).	
	26	Notice of opposition by Atugen against European Patent No. 1 214 945 (March 8, 2006).	
	27	Reply to notice of opposition by Alnylam Europe in the opposition proceedings of European Patent No. 1 214 945 (December 28, 2006).	
	28	Submission by Abbott Laboratories in the opposition proceedings of European Patent No. 1 214 945 (October 30, 2007).	
	29	Submission by Sirna Therapeutics in the opposition proceedings of European Patent: No. 1 214 945 (January 4, 2008).	
	30	Summons to attend oral proceedings in the opposition proceedings of European Patent No. 1 214 945 (May 6, 2008).	
	31	Submission by Alnylam Pharmaceuticals in the opposition proceedings of European Patent No. 1 214 945 (November 20, 2008).	
\downarrow	32	Submission by Sirna Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (November 20, 2008).	

Application Number		10612179		
Filing Date		2003-03-06		
First Named Inventor	Rolan	d Kreutzer		
Art Unit		1635		
Examiner Name Tracy		Ann Vivlemore		
Attorney Docket Numb	or.	A2038-706120		

/T.V./	33	Submission by Silence Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (November 20, 2008).	
	34	Submission by Abbott Laboratories in the opposition proceedings of European Patent No. 1 214 945 (November 20, 2008).	
	35	Statement of Grounds and Particulars of Opposition to Australian Patent Application No. 2005201044, filed by Sirna Therapeutics (December 1, 2008).	
	36	AGAMI, "RNAi and related mechanisms and their potential use for therapy" Current Opin. in Chemical Biology 6:829-834, 2002.	
	37	BOESE et al., "Mechanistic Insights Aid Computational Short Interfering RNA Design" Methods in Enzymology 392:73-95, 2005.	
	38	BRUENIG, "Plant Gene Silencing Regularized" Proc. Natl Acad Science 95:13349-13351, 1998.	
	39	CAMERON et al., "Inhibition of Gene Expression by a Short Sense Fragment" Nucleic Acids Research, 19:469-475, 1991.	
	40	CAPLEN et al., 'dsRNA-Mediated Gene Silencing in Cultured Drosophila Cells: a Tissue Culture Model for the Analysis of RNA Interference' Gene 252:95-105, 2000.	
	41	CAPLEN, "RNAi as a Gene Therapy Approach" Expert. Opin. Biol. Ther. 3:575-586, 2003.	
	42	CHECK, "RNAi to the rescue?" Nature 425:10-12, 2003.	
	43	COBURN et al., "siRNAs: a new wave of RNA-based therapeutics" Jour. Antimicrobial Chemotherapy 51:753-756, 2003.	

(Not for submission under 37 CFR 1.99)

Application Number		10612179	
Filing Date		2003-03-06	
First Named Inventor	Roland Kreutzer		
Art Unit		1635	
Examiner Name	Tracy Ann Vivlemore		
Attorney Docket Number		A2038 706120	

/T.V./	44	COTTEN et al., "Ribozyme Mediated Destruction of RNA in vivo" E					
			MBO J. 8:3861-3866, 198	9.			
	45	CROOKE, "Basic Principles of Antisense Therapeutics" Antisense Verlag, New York, 1998.	Research and Application	, Chapter 1, Springer-			
	46	Declaration of David M. Stalker filed in opposition proceedings for / pages).	ustralian Patent 778474 ((November 4, 2008) (45			
	47	Declaration of David M. Stalker filed in opposition proceedings for Apages).	ustralian Patent 778474 ((November 4, 2008) (17			
	48	Declaration of David Keith Myers filed in opposition proceedings for	Australian Patent 778474	4 (November 4, 2008).			
	49	Exhibit 1 of David Keith Myers Declaration filed in opposition proce 2008).	edings for Australian Pate	nt 778474 (November 4,			
	Exhibit 2 of David Keith Myers Declaration filed in opposition proceedings for Australian Patent 778474 (November 4, 2008).						
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner Signature /Tracy Vivlemore/ Date Considered 04/24/2009				04/24/2009			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.